DNA copy number losses in human neoplasms

American Journal of Pathology

Volumn 155, Issue 3, 1999, Pages 683-694

  Knuutila, Sakari ^a,b   Aalto, Yan ^a   Autio, Kirsi ^a   Björkqvist, Anna Maria ^a   El Rifai, Wa'el ^a   Hemmer, Samuli ^a,b   Huhta, Tarja ^a   Kettunen, Eeva ^a   Kiuru Kuhlefelt, Sonja ^a   Larramendy, Marcelo L ^a   Lushnikova, Tamara ^a   Monni, Outi ^a   Pere, Heini ^a,b   Tapper, Johanna ^a,b   Tarkkanen, Maija ^a   Varis, Asta ^a   Wasenius, Veli Matti ^a,b   Wolf, Maija ^a   Zhu, Ying ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CELL; CANCER GENETICS; CHROMOSOME 13Q; CHROMOSOME 9P; CHROMOSOME LOSS; DNA DETERMINATION; DNA REPAIR; DNA SEQUENCE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0032887168     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65166-8     Document Type: Review

References (197)

1. Knudson AG: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971, 68:820-823
2. Heim S, Mitelman F: Cancer Cytogenetics. 2nd ed. John Wiley & Sons, Inc., New York. 1995
3. Kallioniemi A, Kallioniemi O-P, Sudar D, Rutovitz D. Gray JW, Waldman F. Pinkel D: Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992, 258:818-321
4. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Höglund P, Järvinen H, Kristo P. Pelin K, Ridanpää M, Salovaara R, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, de la Chapelle A, Aaltonen LA: A serine/ threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998, 391:184-187
5. El-Rifai W, Larramendy ML, Björkqvist A-M, Hemmer S, Knuutila S: Optimization of comparative genomic hybridization using fluorochrome conjugated to dCTP and dUTP nucleotides. Lab Invest 1997, 77:699-700
6. Knuutila S, Björkqvist A-M, Autio K, Tarkkanen M, Wolf M, Monni O, Szymanska J, Larramendy ML, Tapper J, Pere H, El-Rifai W, Hemmer S, Wasenius V-M, Vidgren V, Zhu Y: DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 1998, 152:1107-1123
7. Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW, Waldman FM: Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA 1994, 91:2156-2160
8. Bentz M, Plesch A, Stilgenbauer S, Döhner H, Lichter P: Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer 1998, 21:172-175
9. Jost CA, Marin MC, Kaelin Jr. WG: p73 is a human p53-related protein that can induce apoptosis. Nature 1997, 389:191-194
10. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997, 90:809-819
11. Lowsky R, DeCoteau JF, Reitmair AH, Ichinohasama R, Dong WF, Xu Y, Mak TW, Kadin ME, Minden MD: Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of rhombotin-2 (Lmo-2) and Tal-1 (SCL). Blood 1997, 89:2276-2282
12. Le Beau MM, Drabkin H, Glover TW, Gemmill R, Rassool FV, McKeithan TW, Smith DI: An FHIT tumor suppressor gene? Genes Chromosomes Cancer 1998, 21:281-289
13. Beroud C, Joly D, Gallou C, Staroz F, Orfanelli MT, Junien C: Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res 1998, 26:256-258
14. Decker HJH, Weidt EJ, Brieger J: The von Hippel-Lindau tumor suppressor gene: a rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis. Cancer Genet Cytogenet 1997, 93:74-83
15. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilott S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K, Croce CM: The FHIT gene at 3p 14.2 is abnormal in lung cancer. Cell 1996, 85:17-26
16. Simon B, Bartsch D, Barth P, Prasnikar N, Munch K, Blum A, Arnold R, Göke B: Frequent abnormalities of the putative tumor suppressor gene FHIT at 3p 14.2 in pancreatic carcinoma cell lines. Cancer Res 1998, 58:1583-1587
17. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K, Croce CM: FHIT gene alterations in head, and neck squamous cell carcinomas. Proc Natl Acad Sci USA 1996, 93:9770-9775
18. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K: The FHIT gene, spanning the chromosome 3p 14.2 fragile site, and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996, 84:587-597
19. Biéche I, Latil A, Becette V, Lidereau R: Study of FHIT transcripts in normal and malignant breast tissue. Genes Chromosomes Cancer 1998, 23:292-299
20. Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF, Minna JD: FHIT and FRA3B 3p 14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations Cancer Res 1997, 57:2256-2267
21. Thiagalingam S, Lisitsyn NA, Hamaguchi M, Wigler MH, Willson JKV, Markowitz SD, Leach FS, Kinzler KW, Vogelstein B: Evaluation of the FHIT gene in colorectal cancers. Cancer Res 1996, 56:2936-2939
22. Sekido Y, Ahmadian M, Wistuba II, Latif F, Bader S, Wei M-H, Duh F-M, Gazdar AF, Lerman MI, Minna JD: Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene 1998, 16:3151-3157
23. Li L, Bales ES, Peterson CA, Legerski RJ: Characterization of molecular defects in xeroderma pigmentosum group C. Nat Genet 1993, 5:413-417
24. Tanner MM, Karhu RA, Nupponen NN, Borg Å, Baldetorp B, Pejovic T, Fernö M, Killander D, Isola JJ: Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene. Am J Pathol 1998, 153:191-199
25. Hammoud ZT, Kaleem Z, Cooper JD, Sundaresan SR, Patterson GA, Goodfellow PJ: Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4. Cancer Res 1996, 56:4499-4502
26. Leahy MG, Tonks S, Moses JH, Brett AR, Huddart R, Forman D, Oliver RTD, Bishop DT, Bodmer JG: Candidate regions for a testicular cancer susceptibility gene. Hum Mol Genet 1995, 4:1551-1555
27. Bell SM, Zuo J, Myers RM, Knowles MA: Fluorescence in situ hybridization deletion mapping at 4p 16.3 in bladder cancer cell lines refines the localisation of the critical interval to 30 kb. Genes Chromosomes Cancer 1996, 17:108-117
28. Polascik TJ, Cairns P, Chang WY, Schoenberg MP, Sidransky D: Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. Cancer Res 1995, 55:5396-5399
29. Fairman J, Chumakov I, Chinault AC, Nowell PC, Nagarajan L: Physical mapping of the minimal region of loss in 5q-chromosome. Proc Natl Acad Sci USA 1995, 92:7406-7410
30. Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM, Rowley JD: Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 1986, 4:325-345
31. Laurent-Puig P, Beroud C, Soussi T: APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res 1998, 26:269-270
32. Sheng ZM, Marchetti A, Buttitta F, Champeme M-H, Campani D, Bistocchi M, Lidereau R, Callahan R: Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. Br J Cancer 1996, 73:144-147
33. Theile M, Seitz S, Arnold W, Jandrig B, Frege R, Schlag PM, Haensch W, Guski H, Winzer K-J, Barrett JC, Scherneck SA: A defined chromosome 6 fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer. Oncogene 1996, 13:677-685
34. Offit K, Parsa NZ, Gaidano G, Filippa DA, Louie D, Pan D, Jhanwar SC, Dalla-Favera R, Chaganti RSK: 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood 1993, 82:2157-2162
35. Orphanos V, McGown G, Hey Y, Thorncroft M, Santibanez-Koref M, Russell SEH, Hickey I, Atkinson RJ, Boyle JM: Allelic imbalance of chromosome 6q in ovarian tumors. Br J Cancer 1995, 71:666-669
36. Orphanos V, McGown G, Hey Y, Boyle JM, Santibanez-Koref M: Proximal 6q, a region showing allele loss in primary breast cancer. Br J Cancer 1995, 71:290-293
37. Bell DW, Jhanwar SC, Testa JR: Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma. Cancer Res 1997, 57:4057-4062
38. Wan M, Sun T, Vyas R, Zheng J, Granada E, Dubeau L: Suppression of tumorigenicity in human cancer cell lines is controlled by a 2 cM fragment in chromosomal region 6q24-q25. Oncogene 1999, 18: 1545-1551
39. Abdollahi A, Roberts D, Godwin AK, Schultz DC, Sonoda G, Testa JR, Hamilton TC: Identification of a zinc-finger gene at 6q25: a chromosomal region implicated in development of many solid tumors. Oncogene 1997, 14:1973-1979
40. Varrault A, Ciani E, Apiou F, Bilanges B, Hoffman A, Pantaloni C, Bockaert J, Spengler D, Journot L: hZAC encodes a zinc finger protein with antiproliferative properties and maps to a chromosomal region frequently lost in cancer. Proc Natl Acad Sci USA 1998, 95:8835-8840
41. Johansson B, Mertens F, Mitelman F: Cytogenetic deletion maps of hematologic neoplasms: circumstantial evidence for tumor suppressor loci. Genes Chromosomes Cancer 1993, 8:205-218
42. Zenklusen JC, Thompson JC, Troncoso P, Kagan J, Conti CJ: Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res 1994, 54:6370-6373
43. Zenklusen JC, Thompson JC, Klein-Szanto AJ, Conti CJ: Frequent loss of heterozygosity in human primary squamous cell and colon carcinomas at 7q31.1: evidence for a broad range tumor suppressor gene. Cancer Res 1995, 55:1347-1350
44. Shridhar V, Sun QC, Miller OJ, Kalemkerian GP, Petros J, Smith DI: Loss of heterozygosity on the long arm of human chromosome 7 in sporadic renal cell carcinomas. Oncogene 1997, 15:2727-2733
45. Ishwad CS, Ferrell RE, Hanley K, Davare J, Meloni AM, Sandberg AA, Surti U: Two discrete regions of deletion at 7q in uterine leiomyomas. Genes Chromosomes Cancer 1997, 19:156-160
46. Edelson MI, Scherer SW, Tsui LC, Welch WR, Bell DA, Berkowitz RS, Mok SC: Identification of a 1300 kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas. Oncogene 1997, 14:2979-2984
47. Liang H, Fairman J, Claxton DF, Nowell PC, Green ED, Nagarajan L: Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. Proc Natl Acad Sci USA 1998, 95:3781-3785
48. Pedersen B, Ellegaard J: A factor encoded by 7q31 suppresses expansion of the 7q clone and delays cytogenetic progression. Cancer Genet Cytogenet 1994, 78:181-188
49. Richter J, Jiang F, Görög J-P, Sartorius G, Egenter C, Gasser TC, Moch H, Mihatsch MJ, Sauter G: Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997, 57:2860-2864
50. Wagner U, Bubendorf L, Gasser TC, Moch H, Görög J-P, Richter J, Mihatsch MJ, Waldman FM, Sauter G: Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am J Pathol 1997, 151:753-759
51. Takle LA, Knowles MA: Deletion mapping implicates two tumour suppressor genes on chromosome 8p in the development of bladder cancer. Oncogene 1996, 12:1083-1087
52. Farrington SM, Cunningham C, Boyle SM, Wyllie AH, Dunlop MG: Detailed physical and deletion mapping of 8p with isolation of YAC clones from tumour suppressor loci involved in colorectal cancer. Oncogene 1996, 12:1803-1808
53. Vocke CV, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM: Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res 1996, 56:2411-2416
54. Wright K, Wilson PJ, Kerr J, Do K, Hurst T, Khoo S-K, Ward B, Chenevix-Trench G: Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas. Oncogene 1998, 17:1185-1188
55. Yuan B-Z, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC: Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP, Cancer Res 1998, 58:2196-2199
56. Fujiwara Y, Ohata H, Kuroki T, Koyama K, Tsuchiya E, Monden M, Nakamura Y: Isolation of a candidate tumor suppressor gene on chromosome 8p21.3-p22 that is homologous to an extracellular domain of the PDGF receptor ß gene. Oncogene 1995, 20:891-895
57. Seitz S, Rohde K, Bender E, Nothnagel A, Kölble K, Schlag PM, Scherneck S: Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: linkage analysis in German breast cancer families. Oncogene 1997, 14:741-743
58. Van Hul W, Wuyts W, Hendrickx J, Speleman F, Wauters J, De Boulle K, Van Roy N, Bossuyt P, Willems PJ: Identification of a third EXT-like gene (EXTL3) belonging to the EXT gene family. Genomics 1998, 47:230-237
59. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707
60. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stocken E, Day III RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440
61. Liggett WH, Sidransky D: Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998, 16:1197-1206
62. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D: Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995, 11:210-212
63. Jen J, Harper W, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JKV, Kinzler KW, Vogelstein B: Deletion oF p16 and p15 genes in brain tumors. Cancer Res 1994, 54:6353-6358
64. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee W-C, Altomare DA, Nobori T, Olopade Oi, Buckler AJ, Testa JR: p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994, 54:5547-5551
65. INK4B) display frequent homozygous deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemias. Blood 1994, 84: 4038-4044
66. Ohta M, Nagai H, Schimizu M, Rasio D, Berd D, Mastrangelo M, Singh AD, Shields JA, Shields CL, Croce CM, Huebner K: Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res 1994, 54:5269-5272
67. Maelandsmo GM, Berner J-M, Flerenes VA, Forus A, Hovig E, Fodstad Ø, Myklebost O: Homozygous deletion frequency and expression levels of the CDKN2 and CCND1. Br J Cancer 1995, 72:393-398
68. Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC, Godwin AK: Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2 Cancer Res 1995, 55:2150-2157
69. Caldas C. Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994, 8:27-32
70. Foulkes WD, Flanders TY, Pollock PM, Hayward NK: The CDKN2A (p16) gene and human cancer. Mol Med 1997, 3:5-20
71. Fizzotti M, Cimino G, Pisegna S, Alimena G, Quartarone C, Mandell F, Pelicci PG, Lo Coco F: Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 1995, 85:2685-2690
72. Taceuchi S, Bartram CR, Seriu T, Miller CW, Tobler A, Janssen JWG, Reiter A, Ludwig W-D, Zimmermann M, Schwaller J, Lee E, Miyoshi I, Koeffler P: Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 1995, 86:755-760
73. Quesnel B, Preudhomme C, Philippe N, Vanrumpeke M, Dervite I, Lai JL, Bauters F, Wattel E, Fenaux P: p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 1995, 85:657-663
74. Okuda T, Shurtleff SA, Valentine MB, Raimondi SC, Head DR, Behm F, Curcio-Brint AM, Liu Q, Pui C-H, Sherr CJ, Beach D, Look AT, Downing JR: Frequent deletion of p16ink4a/MTS1 and p15ink4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 1995, 85: 2321-2330
75. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH, Tucker MA: Increased risk of pancreatic cancer in melanoma-prone kindreds with p16ink4 mutations. N Engl J Med 1995, 333:970-974
76. Hussussian SJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheanan MD, Clark Jr. WH, Tucker MA, Dracopoli NC: Germline p16 mutations in familial melanoma. Nat Genet 1994, 8:15-21
77. Gruis NA, van der Velden PA, Sandkujil LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W, Frants RR: Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 1995, 10:351-353
78. Heyman M, Rasool O, Brandter LB, Liu Y, Grander D, Söderhäll S, Gustavsson G, Einhorn S: Prognostic importance of p15INK4B and p16INK4 gene inactivation in childhood acute lymphocytic leukemia. J Clin Oncol 1996, 14:1512-1520
79. Habuchi T, Devlin J, Elder PA, Knowles MA: Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene 1995, 11:1671-1674
80. Habuchi T, Yoshida O, Knowles MA: A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: localization of the candidate region within a single 840 kb YAC. Hum Mol Genet 1997, 6:913-919
81. Simoneau AR, Spruck III CH, Gonzalez-Zulueta M, Gonzalgo ML, Chan MF, Tsai YC, Dean M, Steven K, Horn T, Jones PA: Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Res 1996, 56:5039-5043
82. Goldstein AM, Stewart C, Bale AE, Bale SJ, Dean M: Localization of the gene for the nevoid basal cell carcinoma syndrome. Am J Hum Genet 1994, 54:765-773
83. Wicking C, Berkman J, Wainwright B, Chenevix-Trench G: Fine genetic mapping of the gene for nevoid basal cell carcinoma syndrome. Genomics 1994, 22:505-511
84. Bale AE: The nevoid basal cell carcinoma syndrome: genetics and mechanism of carcinogenesis. Cancer Invest 1997, 15:180-186
85. Schofield D, West DC, Anthony DC, Marshal R, Sklar J: Correlation of loss of heterozygosity at chromosome 9q with histological subtype in medulloblastomas. Am J Pathol 1995, 146:472-480
86. Habuchi T, Luscombe M, Elder PA, Knowles MA: Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics 1998, 48:277-288
87. Suzuki K, Ogura T, Yokose T, Nagai K, Mukai K, Kodama T, Nishiwaki Y, Esumi H: Loss of heterozygosity in the tuberous sclerosis gene associated regions in adenocarcinoma of the lung accompanied by multiple atypical adenomatous hyperplasia. Int J Cancer 1998, 79:384-389
88. Tanaka K, Miura N, Satokata I, Miyamoto I, Yoshida MC, Satoh Y, Kondo S, Yasui A, Okayama H, Okada Y: Analysis of a human DNA excision repair gene involved in group A xeroderma pigmentosum and containing a zinc-finger domain. Nature 1990, 348:73-76
89. Johnson RT, Squires S: The XPD complementation group: insights into xeroderma pigmentosum, Cockayne's syndrome and trichothiodystrophy. Mutat Res 1992, 273:97-118
90. Voesten AM, Bijleveld EH, Westerveld A, Hulsebos TJ: Fine mapping of a region of common deletion on chromosome arm 10p in human glioma. Genes Chromosomes Cancer 1997, 20:167-172
91. Ittmann MM: Chromosome 10 alterations in prostate adenocarcinoma. Oncol Rep 1998, 5:1329-1335
92. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC. Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947
93. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R, Ellenson LH: Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997, 57:3935-3940
94. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd JCR: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 1997, 57:3657-3659
95. Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK: Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res 1995, 55:4800-4803
96. Wechsler DS, Shelly CA, Dang CV: Genomic organization of human MXI1, a putative tumor suppressor gene. Genomics 1996, 32:466-470
97. Coleman WB, Esch GL, Borchert KM, McCullough KD, Reid LH, Weissman BE, Smith GJ, Grisham JW: Localization of a putative liver tumor suppressor locus to a 950-kb region of human 11p11.2-p12 using rat liver tumor microcell hybrid cell lines. Mol Carcinog 1997, 19:267-272
98. Stilgenbauer S, Liebisch P, James MR, Schroder M, Schlegelberger B, Fischer K, Bentz M, Lichter P, Dohner H: Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-q23.1 in lymphoproliferative disorders. Proc Natl Acad Sci USA 1996, 93:11837-11841
99. Laake K, Odegård Å, Ikdahl Andersen T, Bukholm IK, Kåresen R, Nesland JM, Ottestad L, Shiloh Y, Borresen-Dale AL: Loss of heterozygosity at 11q23.1 in breast carcinomas: indication for involvement of a gene distal and close to ATM. Genes Chromosomes Cancer 1997, 18:175-180
100. Murakami Y, Nobukuni T, Tamura K, Maruyama T, Sekiya T, Arai Y, Gomyo H, Tanigami A, Ohki M, Cabin D, Frischmeyer P, Hunt P, Reeves RH: Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q. Proc Natl Acad Sci USA 1998, 95:8153-8158
101. Hampton GM, Penny LA, Baergen RN, Larson A, Brewer C, Liao S, Busby-Earle RMC, Williams AWR, Steel CM, Bird CC, Stanbridge EJ, Evans GA: Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. Proc Natl Acad Sci USA 1994, 91:6953-6957
102. Hampton GM, Mannermaa A, Winquist R, Alavaikko M, Blanco G, Taskinen PJ, Kiviniemi H, Newsham I, Cavenee WK, Evans GA: Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res 1994, 54:4586-4589
103. Davis M, Hitchcock A, Foulkes WD, Campbell IG: Refinement of two chromosome 11 regions of loss of heterozygosity in ovarian cancer. Cancer Res 1996, 56:741-744
104. Herbst RA, Larson A, Weiss J, Cavenee WK, Hampton GM, Arden KC: A defined region of loss of heterozygosity at 11q23 in cutaneous malignant melanoma. Cancer Res 1995, 55:2494-2496
105. Bethwaite PB, Koreth J, Herrington CS, McGee JO: Loss of heterozygosity occurs at the D11S29 locus on chromosome 11q23 in invasive cervical carcinoma. Br J Cancer 1995, 71:814-818
106. Koreth J, Bakkenist CJ, McGee JO: Allelic deletions at chromosome 11q22-q23.1 and 11q25-qterm are frequent in sporadic breast but not colorectal cancers. Oncogene 1997, 14:431-437
107. Monni O, Oinonen R, Elonen E, Franssila K, Teerenhovi L, Joensuu H, Knuutila S: Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. Genes Chromosomes Cancer 1998, 21:298-307
108. Rotman G, Shiloh Y: The ATM gene, and protein: possible roles in genome surveillance, checkpoint controls and cellular defense against oxidative stress. Cancer Surv 1997, 29:285-304
109. Siqing Wang S, Esplin ED, Ling Li J, Huang L, Gazdar A, Minna J, Evans GA: Alterations of the PPP2RIB gene in human lung and colon cancer. Science 1998, 282:284-287
110. Golub TR, Barker GF, Lovett M, Gilliland DG: Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994, 77:307-316
111. Romana SP, Mauchauffe M, Coniat ML, Chumakov I, Paslier DL, Berger R, Bernard OA: The t(12;21 ) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 1995, 85:3662-3670
112. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland DG: Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1995, 92:4917-4921
113. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M: t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA 1991, 88:10431-10434
114. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, Chan GC-F, Pui C-H, Grosveld G, Downing JR: TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL, and defines a subgroup of patients with an excellent prognosis. Leukemia 1995, 9:1985-1989
115. Rubnitz JE, Downing JR, Pui C-H, Shurtleff SA, Raimondi SC, Evans WE, Head DR, Crist WM, Rivera GK, Hancock ML, Boyett JM, Buijs A, Grosveld G, G BF: TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol 1997, 15:1150-1157
116. Borkhardt A, Cazzaniga G, Viehmann S, Valsecchi MG, Ludwig WD, Burci L, Mangioni S, Schrappe M, Riehm H, Lampert F, Basso G, Masera G, Harbott J, Biondi A: Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Blood 1997, 90:571-577
117. Liang D-C, Chou T-B, Chen J-S, Shurtleff SA, Rubnitz JE, Downing JR, Pui C-H, Shih L-Y: High incidence of TEL/AML1 fusion resulting from a cryptic t(12;21) in childhood B-lineage acute lymphoblastic leukemia in Taiwan. Leukemia 1996, 10:991-993
118. McLean TW, Ringold S, Neuberg D, Stegmaier K, Tantravahi R, Ritz J, Koeffler HP, Takeuchi S, Janssen JWG, Seriu T, Bartram CR, Sallan SE, Gilliland DG, Golub TR: TEL/AML1 dimerizes, and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996, 88:4252-4258
119. Taceuchi S, Seriu T, Bartram CR, Golub TR, Reiter A, Miyuoshi I, Gilliland DG, Koeffler HP: TEL is one of the targets for deletion on 12p in many cases of childhood B-lineage acute lymphoblastic leukemia. Leukemia 1997, 11:1220-1223
120. Cavé H, Cacheux V, Raynaud S, Brunie G, Bakkus M, Cochaux P, Preudhomme C, Lai JL, Vilmer E, Grandchamp B: ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymhoblastic leukemia. Leukemia 1997, 11:1459-1464
121. Raynaud S, Cavé H, Baens M, Bastard C, Cacheux V, Grosgeorge J, Guidal-Giroux C, Guo C, Vilmer E, Marynen P, Grandchamp B: The 12;21 translocation involving TEL, and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood 1996, 87:2891-2899
122. Cowell JK, Hogg A: Genetics and cytogenetics of retinoblastoma. Cancer Genet Cytogenet 1992, 64:1-11
123. Weinberg RA: Tumor suppressor genes. Science 1991, 254:1138-1146
124. Weinberg RA: The retinoblastoma gene and gene product. Cancer Surveys: Tumour Suppressor Genes, the Cell Cycle and Cancer. Cold Spring Harbor Laboratory Press, New York, 1992, pp 43-57
125. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986, 323:643-646
126. Fung Y-KT, Murphree AL, T'Ang A, Qian J, Hinrichs SH, Benedict WF: Structural evidence for the authenticity of the human retinoblastoma gene. Science 1987, 236:1657-1561
127. Liu Y, Corcoran M, Rasool O, Ivanova G, Ibbotson R, Grander D, lyengar A, Baranova A, Kashuba V, Merup M, Wu X, Gardiner A, Mullenbach R, Poltaraus A, Hultstrom AL, Juliusson G, Chapman R, Tiller M, Cotter F, Gahrton G, Yankovsky N, Zabarovsky E, Einhorn S, Oscier D: Cloning of two candidate tumor suppressor genes within a 10kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene 1997, 15:2463-2473
128. Karhu R, Knuutila S, Kallioniemi O-P, Siitonen S, Aine R, Vilpo L, Vilpo J: Frequent loss of the 11q14-q24 region in chronic lymphocytic leukemia. A study by comparative genomic hybridization. Genes Chromosomes Cancer 1997, 19:286-290
129. Bentz M, Huck K, du Manoir S, Joos S, Werner CA, Fischer K, Döhner H, Lichter P: Comparative genomic hybridization in chronic B-cell leukemias shows a high incidence of chromosomal gains and losses. Blood 1995, 85:3610-3618
130. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Menko FH, Daly PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton MR: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994, 265:2088-2090
131. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Keisell D, Ford D, Tonin P, Biship DT, Spurr NK, Ponder BAJ, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A, Stratton MR: Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792
132. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, Tanner M, Isola J, Barkardottir RB, Borg Å, Kallioniemi O-P: Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997, 57:1222-1227
133. Garkavtsev I, Kazarov A, Gudkov A, Riabowol K: Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat Genet 1996, 14:415-420
134. Zeremski M, Horrigan SK, Grigorian IA, Westbrook CA, Gudkov AV: Localization of the candidate tumor suppressor gene ING1 to human chromosome 13q34. Somat Cell Mol Genet 1997, 23:233-236
135. Maestro R, Piccinin S, Doglioni C, Gasparotto D, Vukosavljevic T, Sulfaro S, Barzan L, Bolocchi M: Chromosome 13q deletion mapping in head, and neck squamous cell carcinomas: identification of two distinct regions of preferential loss. Cancer Res 1996, 56:1146-1150
136. Bockmuhl U, Schwendel A, Dietel M, Petersen I: Distinct patterns of chromosomal alterations in high- and low-grade head and neck squamous cell carcinoma. Cancer Res 1996, 56:5325-5329
137. Bandera CA, Takahashi H, Behbakht K, Liu PC, LiVolsi VA, Benjamin I, Morgan MA, King SA, Rubin SC, Boyd J: Deletion mapping of two potential chromosome 14 tumor suppressor gene loci in ovarian carcinoma. Cancer Res 1997, 57:513-515
138. Chang WY-H, Cairns P, Schoenberg MP, Polascik TJ, Sidransky D: Novel suppressor loci on chromosome 14q in primary bladder cancer. Cancer Res 1995, 55:3246-3249
139. Schwerdtle RF, Winterpacht A, Störkel S, Brenner W, Hohenfellner R, Zabel B, Huber C, Decker H-J: Loss of heterozygosity studies and deletion mapping identify two putative chromosome 14q tumor suppressor loci in renal oncocytomas. Cancer Res 1997, 57:5009-5012
140. Herbers J, Schullerus D, Muller H, Kenck C, Chudek J, Weimer J, Bugert P, Kovacs G: Significance of chromosome arm 14q loss in nonpapillary renal cell carcinomas. Genes Chromosomes Cancer 1997, 19:29-35
141. Wick W, Petersen I, Schmutzler RK, Wolfarth B, Lenartz D, Bierhoff E, Hümmerich J, Müller DJ, Stangl AP, Schramm J, Wiestler OD, von Deimling A: Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer. Oncogene 1996, 12:973-978
142. Baldi A, Esposito V, De Luca A, Fu Y, Meoli I, Giordano GG, Caputi M, Baldi F, Giordano A: Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer. Clin Cancer Res 1997, 3:1691-1697
143. Susini T, Baldi F, Howard CM, Baldi A, Taddei G, Massi D, Rapi S, Savino L, Massi G, Giordano A: Expression of the retinoblastoma-related gene Rb2/p130 correlates with clinical outcome in endometrial cancer. J Clin Oncol 1998, 16:1085-1093
144. Yamamoto H, Itoh F, Hinoda Y, Imai K: Inverse association of cell
145. Yamamoto H, Itoh F, Sakamoto H, Nakajima Y, Une Y, Hinoda Y, Imai K: Association of reduced cell adhesion regulator messenger RNA expression with tumor progression in human hepatocellular carcinoma. Int J Cancer 1997, 74:251-254
146. Filippova GN, Lindblom A, Meincke LJ, Klenova EM, Neiman PE, Collins SJ, Doggert NA, Lobanenkov VV: A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers. Genes Chromosomes Cancer 1998, 22:26-36
147. van Bakel I, Sepp T, Ward S, Yates JR, Green AJ: Mutations in the TSC2 gene: analysis of the complete coding sequence using the protein truncation test (PTT). Hum Mol Genet 1997, 6:1409-1414
148. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, van Roy F: E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995, 14:6107-6115
149. Sato M, Mori Y, Sakurada A, Fujimura S, Horii A: The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum Genet 1998, 103:96-101
150. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM: Localization of gene for human p53 tumour antigen to band 17p13. Nature 1986, 320:84-85
151. Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C: Wild-type p53 activates transcription in vitro Nature 1992, 358: 83-86
152. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B: A model for p53-induced apoptosis. Nature 1997, 389:300-305
153. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991, 253:49-53
154. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 1991, 351:453-456
155. Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, Livingston DM, Parvin JD: BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci USA 1997, 94:5605-5610
156. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62:676-689
157. Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, Conroy L, Clark R, O'Connell P, Cawthon RM, Innis MA, McCormick F: The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990, 63:843-849
158. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271:350-353
159. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero RA, Jr., Meltzer PS, Hahn SA, Kern SE: DPC4 gene in various tumor types. Cancer Res 1996, 56:2527-2530
160. Kim SK, Fan Y, Papadimitrakopoulou V, Clayman G, Hittelman WN, Hong WK, Lotan R, Mao L: DPC4, a candidate tumor suppressor gene, is altered infrequently in head, and neck squamous cell carcinoma Cancer Res 1996, 56:2519-2521
161. Powell SM, Harper JC, Hamilton SR, Robinson CR, Cummings OW: Inactivation of Smad4 in gastric carcinomas. Cancer Res 1997, 57:4221-4224
162. Zhou S, Buckhaults P, Zawel L, Bunz F, Riggins G, Le Dai J, Kern SE, Kinzler KW, Vogelstein B: Targeted deletion of Smad4 shows it is required for transforming growth factor β and activin signaling in colorectal cancer cells. Proc Natl Acad Sci USA 1998, 95:2412-2416
163. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM: Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 1998, 92:645-656
164. Keino-Masu K, Masu M, Hinck L, Leonardo ED, Chan SS, Culotti JG, Tessier-Lavigne M: Deleted in colorectal cancer (DCC) encodes a netrin receptor. Cell 1996, 87:175-185
165. Mehlen P, Rabizadeh S, Snipas SJ, Assa-Munt N, Salvesen GS, Bredesen DE: The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. Nature 1998, 395:801-804
166. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW, Vogelstein B: Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990, 247:49-56
167. Devilee P, van Vliet M, Kuipers-Dijkshoorn N, Pearson PL, Cornelisse CJ: Somatic genetic changes on chromosome 18 in breast carcinomas: is the DCC gene involved? Oncogene 1991, 6:311-315
168. Gao X, Honn KV, Grignon D, Sakr W, Chen YQ: Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res 1993, 53:2723-2727
169. Hohne MW, Halatsch ME, Kahl GF, Weinel RJ: Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. Cancer Res 1992, 52:2616-2619
170. Uchino S, Tsuda H, Noguchi M, Yokota J, Terada M, Saito T, Kobayashi M, Sugimura T, Hirohashi S: Frequent loss of heterozygosity at the DCC locus in gastric cancer. Cancer Res 1992, 52:3099-3102
171. Scheck AC, Coons SW: Expression of the tumor suppressor gene DCC in human gliomas. Cancer Res 1993, 53:5605-5609
172. Horstmann MA, Posl M, Scholz RB, Anderegg B, Simon P, Baumgaertl K, Delling G, Kabisch H: Frequent reduction or loss of DCC gene expression in human osteosarcoma. Br J Cancer 1997, 75: 1309-1317
173. Porfiri E, Secker-Walker LM, Hoffbrand AV, Hancock JF: DCC tumor suppressor gene is inactivated in hematologic malignancies showing monosomy 18. Blood 1993, 81:2696-2701
174. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui L-C, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL, Attisano L: MADR2 maps to 18q21, and encodes a TGF-β-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996, 86:543-552
175. Hemminki A, Tomlinson I, Markie D, Järvinen H, Sistonen P, Björkqvist A-M, Knuutila S, Salovaara R, Bodmer W, Shibata D, de la Chapelle A, Aaltonen L: Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet 1997, 15:87-90
176. Le Merrer M, Legeai-Mallet L, Jeannin PM, Horsthemke B, Schinzel A, Plauchu H, Toutain A, Achard F, Munnich A, Maroteaux P: A gene for multiple exostoses maps to chromosome 19p. Hum Mol Genet 1994, 3:717-722
177. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimers in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993, 74:609-619
178. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. Cell 1995, 80:293-299
179. Kawai T, Matsumoto M, Takeda K, Sanjo H, Akira S: ZIP kinase, a novel serine/threonine kinase which mediates apoptosis: Mol Cell Biol 1998, 18:1642-1651
180. Siciliano MJ, Bachinski L, Dolf G, Carrano AV, Thompson LH: Chromosomal assignments of human DNA repair genes that complement Chinese hamster ovary (CHO) cell mutant. Cytogenet Cell Genet 1987, 46:691-692 (Abstr)
181. Parker C-H, Sancar A: Formation of a ternary complex by human XPA, ERCC1, and ERCC4 (XPF) excision repair proteins. Proc Natl Acad Sci USA 1994, 91:5017-5021
182. Flejter WL, McDaniel LD, Askari M, Friedberg EC, Schultz RA: Characterization of a complex chromosomal rearrangement maps the locus for in vitro complementation of xeroderma pigmentosum group D to human chromosome band 19q13. Genes Chromosomes Cancer 1992, 5:335-342
183. Wang PW, Iannantuoni K, Davis EM, Espinosa III R, Stoffel M, Le Beau MM: Refinement of the commonly deleted segment in myeloid leukemias with a del(20q). Genes Chromosomes Cancer 1998, 21: 75-81
184. Bench AJ, Aldred MA, Humphray SJ, Champion KM, Gilbert JGR, Asimakopoulos FA, Deloukas P, Gwilliam R, Bentley DR, Green AR: A detailed physical and transcriptional map of the region of chromosome 20 that is deleted in myeloproliferative disorders and refinement of the common deleted region. Genomics 1998, 49:351-362
185. Asimakopoulos FA, Green AR: Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders. Br J Haematol 1996, 95:219-226
186. Asimakopoulos FA, White NJ, Nacheva EP, Green AR: The human CD40 gene lies within chromosome 20q deletions associated with myeloid malignancies. Br J Haematol 1996, 92:127-130
187. Ruttledge M, Sarrazin J, Rangaratnam S, Phelan C, Twist E, Merel P, Delattre O, Thomas G, Nordenskjöld M, Collins P, Dumanski J, Rouleau G: Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994, 6:180-184
188. Schofield DE, Beckwith JB, Sklar J: Loss of heterozygosity at chromosome regions 22q11-12 and 11p15.5 in renal rhabdoid tumors. Genes Chromosomes Cancer 1996, 15:10-17
189. Yang-Feng TL, Li S, Han H, Schwartz PE: Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancer. Int J Cancer 1992, 52:575-580
190. Yang-Feng TL, Han H, Chen KC, Li SB, Claus EB, Carcangiu ML, Chambers SK, Chambers JT, Schwartz PE: Allelic loss in ovarian cancer. Int J Cancer 1993, 54:546-551
191. Choi C, Cho S, Horikawa I, Berchuck A, Wang N, Cedrone E, Jhung SW, Lee JB, Kerr J, Chenevix-Trench G, Kim S, Barrett JC, Koi M: Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas. Genes Chromosomes Cancer 1997, 20:234-242
192. Edelson MI, Lau CC, Colitti CV, Welch WR, Bell DA, Berkowitz RS, Mok SC: A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors. Oncogene 1998, 16:197-202
193. Fujino T, Risinger JI, Collins NK, Liu F-S, Nishii H, Takahashi H, Westphal EM, Barrett JC, Sasaki H, Kohler MF, Berchuck A, Boyd J: Allelotype of endometrial carcinoma. Cancer Res 1994, 54:4294-4298
194. Mitra AB, Murry VV, Li RG, Pratap M, Luthra UK, Chaganti RS: Allelotype analysis of cervical carcinoma. Cancer Res 1994, 54: 4481-4487
195. Loupart ML, Adams S, Armour JA, Walker R, Brammar W, Varley J: Loss of heterozygosity on the X chromosome in human breast cancer. Genes Chromosomes Cancer 1995, 13:229-238
196. Thrash-Bingham CA, Salazar H, Greenberg RE, Tartof KD: Loss of heterozygosity studies indicate that chromosome arm 1p harbors a tumor suppressor gene for renal oncocytomas. Genes Chromosomes Cancer 1996, 16:64-67
197. Knuutila S, Aalto Y, Autio U, Bjorkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, Lushnikova T, Monni O, Pere H, Tapper J, Tarkkanen M, Varis A, Wasenius VM, Wolf M, Zhu Y: DNA copy number losses in human neoplasms. Am J Pathol Online 1999, 155:683-694